Centene (NYSE:CNC) Price Target Raised to $73.00

Centene logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Royal Bank of Canada raised Centene’s price target to $73 from $71, maintaining a “sector perform” rating; the new target implies 11.65% upside from the stock’s current price.
  • Analyst sentiment is mixed: Centene has a consensus “Hold” rating and a $75.20 average price target, based on nine Buy, eleven Hold, and one Sell rating.
  • Centene reported quarterly EPS of $0.58, beating the $0.10 consensus estimate, while revenue of $50.65 billion also exceeded expectations.
  • Interested in Centene? Here are five stocks we like better.

Centene (NYSE:CNC - Get Free Report) had its price target increased by research analysts at Royal Bank Of Canada from $71.00 to $73.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a "sector perform" rating on the stock. Royal Bank Of Canada's target price suggests a potential upside of 11.65% from the stock's current price.

Several other research analysts also recently commented on the stock. Zacks Research downgraded shares of Centene from a "strong-buy" rating to a "hold" rating in a report on Monday, October 5th. Robert W. Baird lifted their target price on Centene from $66.00 to $71.00 and gave the stock a "neutral" rating in a report on Wednesday, October 28th. Barclays boosted their target price on Centene from $80.00 to $82.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 28th. Wells Fargo & Company increased their price target on Centene from $69.00 to $75.00 and gave the company an "equal weight" rating in a research note on Friday, October 30th. Finally, Cantor Fitzgerald raised their price target on Centene from $75.00 to $79.00 and gave the company an "overweight" rating in a report on Wednesday, October 28th. Nine analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $75.20.

View Our Latest Stock Analysis on Centene

Centene Trading Down 0.3%

Shares of CNC opened at $65.38 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.16 and a quick ratio of 1.16. Centene has a 1 year low of $31.63 and a 1 year high of $78.08. The company has a 50 day simple moving average of $67.46 and a two-hundred day simple moving average of $57.06. The firm has a market cap of $32.37 billion, a P/E ratio of 22.35, a price-to-earnings-growth ratio of 0.39 and a beta of 1.07.

Centene (NYSE:CNC - Get Free Report) last released its quarterly earnings data on Tuesday, October 27th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.48. The firm had revenue of $50.65 billion for the quarter, compared to analysts' expectations of $47.12 billion. Centene had a net margin of 0.72% and a return on equity of 12.15%. The company's revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.50 earnings per share. On average, equities analysts expect that Centene will post 5.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Centene news, General Counsel Christopher Koster sold 56,500 shares of Centene stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $66.90, for a total value of $3,779,850.00. Following the completion of the transaction, the general counsel directly owned 248,854 shares of the company's stock, valued at $16,648,332.60. This trade represents a 18.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.37% of the stock is owned by company insiders.

Institutional Trading of Centene

Several hedge funds have recently made changes to their positions in the business. Frank Rimerman Advisors LLC grew its position in Centene by 3.7% in the third quarter. Frank Rimerman Advisors LLC now owns 4,521 shares of the company's stock worth $281,000 after acquiring an additional 163 shares in the last quarter. Journey Retirement Planning & Investment Management LLC raised its position in Centene by 3.9% during the third quarter. Journey Retirement Planning & Investment Management LLC now owns 4,652 shares of the company's stock valued at $289,000 after purchasing an additional 175 shares during the period. Meeder Asset Management Inc. raised its position in Centene by 0.8% during the third quarter. Meeder Asset Management Inc. now owns 25,069 shares of the company's stock valued at $1,557,000 after purchasing an additional 208 shares during the period. Grove Bank & Trust lifted its stake in shares of Centene by 2.0% in the 3rd quarter. Grove Bank & Trust now owns 11,294 shares of the company's stock valued at $702,000 after purchasing an additional 220 shares during the last quarter. Finally, GoalVest Advisory LLC lifted its stake in shares of Centene by 25.9% in the 3rd quarter. GoalVest Advisory LLC now owns 1,122 shares of the company's stock valued at $70,000 after purchasing an additional 231 shares during the last quarter. 93.63% of the stock is currently owned by hedge funds and other institutional investors.

Centene Company Profile

(Get Free Report)

Centene Corporation is a U.S. health care company that provides managed care and related services, primarily for people enrolled in government-sponsored health programs. Its offerings include Medicaid and Medicare plans, as well as health insurance sold through the Affordable Care Act marketplace. Centene serves members through health plans and a network of health care providers. Its businesses include Ambetter, which offers marketplace health plans, and Wellcare, which provides Medicare-related coverage.

See Also

Analyst Recommendations for Centene (NYSE:CNC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Centene Right Now?

Before you consider Centene, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centene wasn't on the list.

While Centene currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines